Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation.

Technical analysis for Cytokinetics Incorporated CYTK including support levels resistance levels and stop losses for CYTK ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14.Invest with ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030 ...

Investors in Cytokinetics Inc (Symbol: CYTK) saw new options begin trading today, for the September 19th expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...